
Frequent cannabis use has been linked to a higher burden of seizures in adults with drug-resistant epilepsy, according to a new study published in Epilepsia. Researchers observed more than double the number of convulsive episodes among participants who reported using the substance most days.
Study population and methods
The investigation examined 64 adults admitted to a specialized epilepsy monitoring unit between 2019 and 2024. All patients had failed to achieve control with at least two antiseizure drugs, prompting clinicians to record seizure activity in real time.
About one-third of them reported using cannabis recreationally most days. Among these frequent users, 90% experienced generalized tonic-clonic seizures, the type most associated with injury and sudden unexpected death, whereas roughly half of the non-using group did not report such events.
Key findings
Lead author Dr. Aaron F. Struck highlighted that the association warrants direct discussion with patients, especially those self-medicating for insomnia or anxiety. “There isn’t definitive data that cannabis use worsens epilepsy,” he said. “But if someone is using cannabis to help with anxiety or sleep, I’d prefer to treat those problems with drugs we understand rather than something largely unregulated whose impact on the brain we don’t really know.”
Dr. Struck noted that the research was prompted by a pattern he observed in his practice: patients with severe seizures lacking typical risk factors often shared a history of high-potency, frequent cannabis consumption.
While a purified cannabidiol (CBD) formulation is FDA-approved for certain epilepsy syndromes, it contains no tetrahydrocannabinol (THC). Animal studies suggest CBD may suppress seizures, whereas THC could have the opposite effect. Recreational products now trend toward higher THC and lower CBD levels.
Comparing 22 frequent users with 42 nonusers, the study found that the former group entered the monitoring unit an average of 5 years after their first seizure, compared with 18 years for the latter. Despite a shorter disease duration, frequent users required more antiseizure medications at discharge.
Among the 15 frequent users whose timelines could be traced, all started using cannabis before experiencing their first seizure, reducing the likelihood that they turned to the drug as a therapeutic response.
Epilepsy this severe usually leaves visible scarring on the hippocampus, a seahorse-shaped structure deep in the brain that is central to memory where many seizures begin. But frequent users’ brain scans looked largely normal, which indicated to Struck that something other than the usual disease process was going on. THC acts on receptors densest in those same brain regions, suggesting these patients’ seizures may arise from damage to how brain circuits are firing rather than from physical damage.
The team is designing a larger, multisite study, including geographic regions with distinct cannabis legalization histories and data on use patterns, such as how many people consume cannabis, at what ages, and in what modality, to reach a more diverse group of patients. Instead of having patients report their own cannabis use, the researchers plan to incorporate objective measures at admission for a more accurate gauge of what people actually consume.
“Right now, the honest answer when a patient asks whether their cannabis use is affecting their seizures is that we’re not sure,” said co-author Dr. Santiago Philibert-Rosas. “Larger studies will help us give them a real answer—how much matters and whether stopping helps—so they can make an informed decision.”
Demographic Profile of Frequent Users and Study Authorship
Philibert-Rosas said patients in their 20s, mostly male, without the usual risk factors for epilepsy, showed rapid seizure escalation from onset to monitoring-unit admission.
The study, titled “Frequent cannabis use and the association with seizure burden in drug-resistant epilepsy,” lists authors Philibert-Rosas S, Guston KA, Kalkach-Aparicio M, Keller A, Semia S, Imhoff-Smith T, Brace CJ, Haworth SE, Branco de Paiva F, Almane D, Williams J, Josiah A, Nix B, Hermann BP, Adluru N, Jones JE, and Struck AF.
Leave a Reply